The cytotoxic effect of Bowman-Birk isoinhibitors, IBB1 and IBBD2, from soybean (Glycine max) on HT29 human colorectal cancer cells is related to their intrinsic ability to inhibit serine proteases

Molecular Nutrition and Food Research

Volumn 54, Issue 3, 2010, Pages 396-405

  Clemente, Alfonso ^a   Moreno, Francisco Javier ^b   Marín Manzano, Maria del Carmen ^a   Jiménez, Elisabeth ^a   Domoney, Claire ^c  

^a CSIC   (Spain)

^b INSTITUTO DE FERMENTACIONES INDUSTRIALES CSIC   (Spain)

^c JOHN INNES CENTRE   (United Kingdom)

Author keywords

Bowman Birk inhibitors; Cell proliferation; HT29 cells; Protease inhibitory activity; Soybean

Indexed keywords

ANTINEOPLASTIC AGENT; BOWMAN BIRK INHIBITOR; CHYMOTRYPSIN; ISOPROTEIN; SERINE PROTEINASE INHIBITOR; TRYPSIN INHIBITOR;

ADENOCARCINOMA; ALKYLATION; ARTICLE; CELL CYCLE G0 PHASE; CELL PROLIFERATION; CELL STRAIN HT29; CELL SURVIVAL; CHEMISTRY; COLORECTAL TUMOR; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; HUMAN; IC 50; ISOLATION AND PURIFICATION; PATHOLOGY; PEPTIDE MAPPING; PROTEIN DOMAIN; SEQUENCE ALIGNMENT; TIME;

ADENOCARCINOMA; ALKYLATION; ANTICARCINOGENIC AGENTS; CELL PROLIFERATION; CELL SURVIVAL; CHYMOTRYPSIN; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; G0 PHASE; HT29 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; PEPTIDE MAPPING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN ISOFORMS; SEQUENCE ALIGNMENT; SERINE PROTEINASE INHIBITORS; TIME FACTORS; TRYPSIN INHIBITOR, BOWMAN-BIRK SOYBEAN; TRYPSIN INHIBITORS;

GLYCINE MAX;

EID: 77649316496     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.200900122     Document Type: Article

References (42)

1. Cummings, J. H., Bingham, S. A., Fortnightly review - diet and the prevention of cancer. Br. Med. J. 1998, 317, 1636-1640.
2. Reddy, B. S., Novel approaches to the prevention of colon cancer by nutritional manipulation and chemoprevention. Cancer Epidemiol. Biomark. Prev. 2000, 9, 239-247.
3. Kennedy, A. R., Billings, P. C., Wan, X. S., Newberne, P. M., Effects of Bowman-Birk in-hibitor on rat colon carcinogenesis. Nutr. Cancer 2002, 43, 174-186.
4. Clemente, A., Domoney, C., Biological significance of polymorphism in plant protease inhibitors from the Bowman-Birk class. Curr. Prot. Pept. Sci. 2006, 7, 201-216.
5. Clemente, A., Domoney, C., in: Govil, J. N., Singh, V. K., Sharma, R. K. (Ed.), Recent Progress in Medicinal Plants (Vol. 20) - Therapeutic properties of legume protease inhibitors from the Bowman-Birk class, SCI Tech Publishing LLC, Houston 2007, pp. 397-417.
6. Clemente, A., Jiménez, E., Marín-Manzano, M. C., Rubio, L. A., Functional Bowman-Birk inhibitors survive gastro-intestinal digestion at the terminal ileum of cannulated pigs fed chickpea-based diets. J. Sci. Food Agric. 2008, 88, 523-531.
7. Marín-Manzano, M. C., Ruiz, R., Jimenez, E., Rubio, L. A., Clemente, A., Anti-carcinogenic Bowman-Birk inhibitors from soybean survive fermentation in active form using faecal inoculum and do not affect the microbiota composition. Br. J. Nutr. 2009, 101, 967-971.
8. Chen, P., Rose, J., Love, R., Wei, C. H., Wang, B. C., Reactive sites of an anticarcinogenic Bowman-Birk proteinase-inhibitor are similar to other trypsin-inhibitors. J. Biol. Chem. 1992,267,1990-1994.
9. Clemente, A., Vioque, J., Sanchez-Vioque, R., Pedroche, J. et al. Factors affecting the in vitro digestibility of chickpea albumins. J. Sci. Food Agric. 2000, 80, 79-84.
10. Qi, R. F., Song, Z. W., Chi, C. W., Structural features and molecular evolution of Bowman-Birk protease inhibitors and their potential application. Acta Biochim. Biophys. Sin. 2005,37,283-292.
11. St Clair, W., Billings, P., Carew, J., Keller-McGandy, C. et al., Suppression of dimethylhydrazine-induced carcinogenesis in mice by dietary addition of the Bowman-Birk protease inhibitor. Cancer Res. 1990, 50, 580-586.
12. Billings, P. C., Brandon, D. L., Habres, J. M., Internalization of the Bowman-Birk protease inhibitor by intestinal epithelial cells. Eur. J. Cancer. 1991, 27, 903-908.
13. Fernandes, A. O., Banerji, A. P., Inhibition of benzopyrene-induced forestomach tumors by field bean protease inhibitor(s). Carcinogenesis 1995, 16, 1843-1846.
14. Ware, H. W., Wan, S., Newberne, P., Kennedy, A. R., Bowman-Birk concentrate reduces colon inflammation in mice with dextran sulphate sodium-induced ulcerative colitis. Digest. Dis. Sci. 1999, 44, 986-990.
15. Domoney, C., Welham, T., Ellis, N., Mozzanega, P., Turner, L., Three classes of proteinase inhibitor gene have distinct but overlapping patterns of expression in Pisum sativum plants. Plant Mol. Biol. 2002, 48, 319-329.
16. Sonnante, G., De Paolis, A., Pignone, D., Bowman-Birk inhibitors in Lens: identification and characterization of two paralogous gene classes in cultivated lentil and wild relatives. Theor. Appl. Genet. 2005, 110, 596-604.
17. Yavelow, J., Collins, M., Birk, Y., Troll, W., Kennedy, A. R., Nanomolar concentrations of Bowman-Birk soybean protease inhibitor suppress X-ray induced transformation in vitro. Proc. Natl. Acad. Sci. USA 1985, 82, 5395-5399.
18. Ware, J. H., Wan, X. S., Rubin, H., Schechter, N. M., Kennedy, A.-R., Soybean Bowman-Birk protease inhibitor is a highly effective inhibitor of human mast cell chymase. Arch. Biochem. Biophys. 1997, 344, 133-138.
19. Clemente, A., MacKenzie, D. A., Jeenes, D. J., Domoney, C., The effect of variation within inhibitory domains on the activity of pea protease inhibitors from the Bowman-Birk class. Protein Express. Purif. 2004, 36, 106-114.
20. Clemente, A., Gee, J. M., Johnson, I. T., MacKenzie, D. A., Domoney, C., Pea (Pisum sativum L.) protease inhibitors from the Bowman-Birk class influence the growth of human colorectal adenocarcinoma HT29 cells in vitro. J. Agric. Food Chem. 2005, 53, 8979-8986.
21. Domoney, C., Welham, T., Trypsin inhibitors in Pisum: variation in amount and pattern of accumulation in developing seed. Seed Sci. Res. 1992, 2, 147-154.
22. Copeland, R. A., Lombardo, D., Giannaras, J., Dedicco, C. P., Estimating Ki values for tight-binding inhibitors from dose-response plots. Bioorg. Med. Chem. Lett. 1995, 5, 1947-1952.
23. Schechter, I., Berger, A., On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. 1967,27,157-162.
24. Ferrasson, E., Quillien, L., Gueguen, J., Proteinase inhibitors from pea seeds: purification and characterization. J. Agric. Food Chem. 1997, 45, 127-131.
25. Ragg, E. M., Galbusera, V., Scarafoni, A., Negri, A. et al., Inhibitory properties and solution structure of a potent Bowman-Birk protease inhibitor from lentil (Lens culinaris L.) seeds. FEBS J. 2006, 273, 4024-4039.
26. Scarafoni, A., Consonni, A., Galbusera, V., Negri, A. et al., Identification and characterization of a Bowman-Birk inhibitor active towards trypsin but not chymotrypsin in Lupinus albus seeds. Phytochemistry 2008, 69, 1820-1825.
27. Pan, M. H., Ho, C. T., Chemopreventive effects of natural dietary compounds on cancer development. Chem. Soc. Rev. 2008, 37, 2558-2574.
28. Lao, C. D., Brenner, D. E., Strategies for prevention of colorectal cancer: pharmaceutical and nutritional interventions. Curr. Treat. Options Oncol. 2004, 5, 417-426.
29. Billings, P. C., Newberne, P., Kennedy, A. R., Protease inhibitor suppression of colon and anal gland carcinogenesis induced by dimethylhydrazine. Carcinogenesis 1990, 11,1083-1086.
30. Hernandez-Ledesma, B., Hsieh, C. C., de Lumen, B. O., Lunasin and Bowman-Birk protease inhibitor (BBI) in US commercial soy foods. Food Chem. 2009, 115, 574-580.
31. Kennedy, A. R., The Bowman-Birk inhibitor from soybean as an anticancer agent. J. Clin. Am. Nutr. 1998, 68, 1406S-1412S.
32. Rayas-Duarte, P., Bergeron, D., Nielsen, S. S., Screening of heat-stable trypsin inhibitors in dry beans and their partial purification from great northern beans (Phaseolus vulgaris) using anhydrotrypsin-Sepharose affinity chromatography. J. Agric. Food Chem. 1992, 40, 32-42.
33. Osman, M. A., Reid, P. M., Weber, C. W., Thermal inactivation of tepary bean (Phaseolus acutifolius), soybean and lima bean protease inhibitors: effect of acidic and basic pH. Food Chem. 2002, 78, 419-423.
34. Kennedy, A. R., Szuhaj, B. F., Newberne, P. M., Billings, P. C., Preparation and production of a cancer chemopreventive agent. Bowman-Birk inhibitor concentrate. Nutr. Cancer 1993, 19, 281-302.
35. Turk, B., Targeting proteases: successes, failures and future prospects. Nat. Rev. Drug Discov. 2006, 5, 785-799.
36. Darmoul, D., Gratio, V., Devaud, H., Lehy, T., Laburthe, M., Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells. Am. J. Pathol. 2003,162,1503-1513.
37. Lee, S. L., Dickson, R. B., Lin, C. Y., Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J. Biol. Chem. 2000, 275, 36720-36725.
38. Bhatt, A. S., Takeuchi, T., Ylstra, B., Ginzinger, D. et al., Quantitation of membrane type serine protease 1 (MT-SP1) in transformed and normal cells. Biol. Chem. 2006, 384, 257-266.
39. Bugge, T. H., List, K., Szabo, R., Matriptase-dependent cell surface proteolysis in epithelial development and pathogenesis. Front. Biosci. 2007, 12, 5060-5070.
40. Yamasaki, Y., Satomi, S., Murai, N., Tsuzuki, S., Fushiki, T., Inhibition of membrane-type serine protease 1/matriptase by natural and synthetic protease inhibitors. J. Nutr. Sci. Vitaminol. 2003, 49, 27-32.
41. Kisselev, A. F., Callard, A., Goldberg, A. L., Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. J. Biol. Chem. 2006, 281, 8582-8590.
42. Chen, Y. W., Huang, S. C., Lin-Shiau, S. Y., Lin, J. K., Bowman-Birk inhibitor abates proteasome function and suppresses the proliferation of MCF7 breast cancer cells through accumulation of MAP kinase phosphatase-1. Carcinogenesis 2005, 26, 1296-1306.